Navigation Links
Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
Date:5/22/2013

CAMBRIDGE, Mass., May 22, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that John Reynders will join Moderna in early July as its first Chief Information Officer.

Reynders is a proven leader in the design and implementation of information systems underlying all phases of drug development, from discovery to translation, clinical operations and commercial preparedness. John has also been at the vanguard of the pharmaceutical industry's efforts in big data analytics, cloud-based computing, and innovation networks. He joins Moderna from AstraZeneca, where he served as Vice President of R&D Information, and has held senior leadership positions over the past decade at Johnson & Johnson, Lilly, and Celera Genomics.

"We are building a company capable of driving innovation on a scale and at a pace that were unimaginable until recently, and our information systems must be able to fuel that vision," said Stephane Bancel , founding president and CEO of Moderna. "John has long been on the forefront of the information revolution that is reshaping drug development and healthcare, and he has a strong vision for how we can design an information resource capable of propelling Moderna – and the entire field of messenger RNA therapeutics™ – well into the future."

Reynders will lead a team at Moderna in creating an information infrastructure critical to all aspects of the company's innovation model, including the use of genomic data in drug design; the integration and instant sharing of knowledge from a variety of preclinical and clinical settings; and the seamless interaction of a wide network of collaborators, partners, and potential spinoff companies.

"It is tremendously exciting to be involved in designing the drug company of the future at this critical moment in Moderna's scale up, when knowledge of the potential application of messenger RNA therapeutics™ is exploding," Reynders said. "For Moderna and the entire field to fully capitalize on this profound advance for patients will require a full end-to-end informatics integration of the Moderna pipeline, creating the industry's first fully digital biotech. It will also require all of us to design new ways of working together, not just within the walls of Moderna but with a vast network of collaborators around the world. This is a once in a lifetime opportunity and I am proud to be a part of it."

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate including 120 patent applications with 6,500 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs – initially for rare diseases and oncology – while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Harvard University and Massachusetts Institute of Technology. Visit www.modernatx.com to learn more.

For information contact:
Dan Quinn
Feinstein Kean Healthcare
617-761-6732
dan.quinn@fkhealth.com


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Resource Provides Herb Industry With Sources of Quality Specifications
2. Garage Start-ups Now Possible in Life Sciences Industry
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
5. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
6. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
7. Prolongs Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran
8. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. Live Press Briefing on Findings of Biomedical Industry CEO Survey
11. Life Technologies Plant in Austin, Texas Named One of IndustryWeeks Top Ten Best Plants for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments ... the lab to fully automated pilot plants and equipment for industrial manufacturing. ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... While art ... are much more closely connected than one might think. A Mesh Is Also ... open at the University City Science Center’s Esther Klein Gallery (EKG) on August 17 ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection took ... This inspection was conducted as part of a routine Bioresearch Monitoring Program (BIMO) ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):